Geron Corp. (NASDAQ:GERN)‘s stock had its “outperform” rating restated by equities research analysts at FBR & Co in a research report issued to clients and investors on Thursday. They currently have a $5.00 price objective on the biopharmaceutical company’s stock. FBR & Co’s price objective points to a potential upside of 125.23% from the company’s current price.

A number of other equities research analysts also recently weighed in on GERN. Zacks Investment Research raised Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 target price for the company in a report on Friday, August 5th. BTIG Research initiated coverage on Geron Corp. in a report on Friday, August 19th. They set a “neutral” rating for the company. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $5.00 target price (down previously from $10.00) on shares of Geron Corp. in a report on Tuesday, September 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $5.00.

Analyst Recommendations for Geron Corp. (NASDAQ:GERN)

Shares of Geron Corp. (NASDAQ:GERN) traded down 1.33% during midday trading on Thursday, reaching $2.22. 2,708,332 shares of the company’s stock were exchanged. The stock has a market cap of $353.29 million, a PE ratio of 277.50 and a beta of 2.63. The company’s 50 day moving average is $2.61 and its 200-day moving average is $2.79. Geron Corp. has a 12 month low of $1.84 and a 12 month high of $5.30.

Geron Corp. (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. Geron Corp. had a return on equity of 0.89% and a net margin of 3.39%. The business earned $0.21 million during the quarter, compared to the consensus estimate of $0.38 million. During the same quarter last year, the firm posted ($0.06) EPS. The company’s quarterly revenue was down 15.9% on a year-over-year basis. Equities analysts forecast that Geron Corp. will post ($0.23) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of GERN. IFP Advisors Inc increased its position in Geron Corp. by 1.9% in the first quarter. IFP Advisors Inc now owns 35,090 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 650 shares during the period. Bank of Montreal Can bought a new position in Geron Corp. during the second quarter worth approximately $108,000. LPL Financial LLC increased its position in Geron Corp. by 81.0% in the first quarter. LPL Financial LLC now owns 35,750 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 16,000 shares during the period. Bellevue Group AG bought a new position in Geron Corp. during the first quarter worth approximately $131,000. Finally, TFS Capital LLC bought a new position in Geron Corp. during the second quarter worth approximately $145,000. 38.09% of the stock is owned by institutional investors and hedge funds.

About Geron Corp.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

5 Day Chart for NASDAQ:GERN

Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with MarketBeat.com's FREE daily email newsletter.